Package insert / prescribing information
Generic name: fluocinolone acetonide
Dosage form: topical solution
Drug class: Topical steroids
Medically reviewed by Drugs.com. Last updated on Dec 1, 2020.
On This Page
Fluocinolone Solution Description
Fluocinolone Acetonide Topical Solution, 0.01% is intended for topical administration. The active component is the corticosteroid ﬂuocinolone acetonide, which has the chemical name pregna-1, 4-diene-3, 20-dione, 6, 9-diﬂuoro-11, 21-dihydroxy-16, 17-[(1-methylethylidene) bis (oxy)]-, (6α, 11β, 16α)-. It has the following chemical structure:
Fluocinolone Acetonide Topical Solution USP, 0.01% contains ﬂuocinolone acetonide 0.1 mg/mL in a water-washable base of anhydrous citric acid and propylene glycol.
Fluocinolone Solution - Clinical Pharmacology
Topical corticosteroids share anti-inﬂammatory, anti-pruritic and vasoconstrictive actions.
The mechanism of anti-inﬂammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efﬁcacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efﬁcacy in man.
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.
Topical corticosteroids can be absorbed from normal intact skin. Inﬂammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses ( see DOSAGE AND ADMINISTRATION) .
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
INDICATIONS AND USAGE
Fluocinolone Acetonide Topical Solution USP, 0.01% is indicated for the relief of the inﬂammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.
Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS—Pediatric Use).
If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues. When used on intertriginous or flexor areas, or on the face, this may occur even with short-term use.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
Information For Patients
Patients using topical corticosteroids should receive the following information and instructions:
- This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
- Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
- The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
- Patients should report any signs of local adverse reactions, especially under occlusive dressing.
- Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.
The following tests may be helpful in evaluating the HPA axis suppression:
Urinary free cortisol test
ACTH stimulation test
Carcinogenesis, Mutagenesis and Impairment of Fertility
Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.
Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.
Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.
Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalmic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to bodyweight ratio.
Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:
||Allergic contact dermatitis
||Maceration of the skin
Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects ( SeePRECAUTIONS).
DOSAGE AND ADMINISTRATION
Fluocinolone Acetonide Topical Solution USP, 0.01% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.
Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.
If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
How is Fluocinolone Solution Supplied
Fluocinolone Acetonide Topical Solution USP, 0.01% 60 mL Bottle with applicator tip - NDC 21922-003-01
Store at room temperature 15-25°C (59-77°F); avoid freezing and excessive heat above 40°C (104°F).
To report SUSPECTED ADVERSE REACTIONS, contact Encube Ethicals Private Limited at 1-833-285-4151 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Encube Ethicals Pvt. Ltd.
Plot No. C1, Madkaim Ind. Estate,
Madkaim, Post Mardol, Ponda, Goa-403 404, India.
Encube Ethicals, Inc.
200 Meredith Avenue,
Durham, NC 27713
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FLUOCINOLONE ACETONIDE TOPICAL SOLUTION USP, 0.01%
CARTON - 60mL
FLUOCINOLONE ACETONIDE TOPICAL SOLUTION USP, 0.01%
BOTTLE - 60mL
|FLUOCINOLONE ACETONIDE TOPICAL SOLUTION USP, 0.01%
fluocinolone acetonide topical solution usp, 0.01% solution
|Labeler - Encube Ethicals Private Limited (915834105)|
|Registrant - Encube Ethicals Private Limited (915834105)|
|Encube Ethicals Private Limited||725076298||analysis(21922-003), manufacture(21922-003)|
More about fluocinolone topical
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (9)
- Pricing & coupons
- Drug class: topical steroids
- Prescribing Information
- Fluocinolone (FDA)
- Fluocinolone Cream (FDA)
- Fluocinolone Oil (FDA)
- Fluocinolone Ointment (FDA)
- Fluocinolone Scalp Oil (FDA)